Zydus receives final approval from the USFDA for Bumetanide Tablets USP

Ahmedabad, 2 May, 2018

Zydus Cadila has received the final approval from the USFDA to market Bumetanide Tablets USP in the strengths of 0.5 mg, 1 mg, and 2 mg. It is used to treat edema associated with congestive heart failure, hepatic and renal disease, including the nephrotic syndrome. It will be manufactured at the group's manufacturing facility at Baddi.

The group now has more than 185 approvals and has so far filed over 320 ANDAs since the commencement of the filing process in FY 2003-04.

About Zydus Cadila

Zydus Cadila is an innovative, global pharmaceutical company that discovers, develops, manufactures and markets a broad range of healthcare therapies. The group employs over 21,000 people worldwide and is dedicated to creating healthier communities globally. Zydus aspires to be a research-based pharmaceutical company by 2020.

***